ArticleFrontiers in oncology2026
Using period analysis to timely provide serial data on long-term survival for liver cancer patients from China.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Timely evaluation of long-term survival in liver cancer is essential for assessing early detection and screening efficacy. However, population-based survival data in China remain scarce, particularly for multi-decade analyses. This study systematically evaluated age-standardized 5-year relative survival (RS) in Taizhou, eastern China, and quantified temporal improvements from 2004 to 2023. Methods: A retrospective cohort of 12,032 liver cancer patients diagnosed in Taizhou (2004-2023) was analyzed. Period analysis was used to compute age-standardized 5-, 10-, 15-, and 20-year RS rates, stratified by gender, age, and urban versus rural residence. Survival estimates were derived using actuarial methods with adjustments for competing mortality risks based on regional life tables. Results: The 5-year RS for patients during 2019-2023 was 37.32%, significantly exceeding earlier periods (29.13% for 2014-2023, 23.00% for 2009-2023, and 5.56% for 2004-2023). Female patients consistently exhibited higher survival (39.23% vs. 37.26% for males), with a pronounced age gradient 5-year RS declined from 45.71% in patients <45 years to 26.05% in those >74 years. The urban-rural survival gap narrowed, with urban areas showing 37.83% versus 37.25% in rural areas (2019-2023). Conclusion: This study provides the most current population-based long-term RS data for liver cancer in Taizhou, offering a critical benchmark for enhancing early detection and screening programs in eastern China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.